Gulam Abbas Manji

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

This study shows that combining gemcitabine with CXCR4 inhibitors and anti-PD1 therapy improves immune response and survival in pancreatic cancer models.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.